With this in mind, we are taking practical steps from a balance sheet management standpoint to provide ourselves with options in the event any additional capital is beneficial or needed down the road, be it to fund M&A and business development, organic growth or additional working capital for accounts receivable and inventory. To that extent, today, we are announcing a Letter of Intent with a large US based lender for a revolving credit facility of up to $25 million, which allows CorMedix to access certain tranches of debt depending on our run rate of accounts receivable. The credit facility will not require us to draw any minimum amount and will be a helpful instrument for managing our balance sheet and working capital in a non-dilutive manner.